The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global PARP Inhibitors for Breast Cancer Market Research Report 2025

Global PARP Inhibitors for Breast Cancer Market Research Report 2025

Publishing Date : Mar, 2025

License Type :
 

Report Code : 1718678

No of Pages : 68

Ask Your Query
Synopsis
The global PARP Inhibitors for Breast Cancer market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for PARP Inhibitors for Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for PARP Inhibitors for Breast Cancer is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for PARP Inhibitors for Breast Cancer in Hospital is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of PARP Inhibitors for Breast Cancer include AstraZeneca, Everest Pharmaceuticals and Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for PARP Inhibitors for Breast Cancer, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding PARP Inhibitors for Breast Cancer.
Report Scope
The PARP Inhibitors for Breast Cancer market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global PARP Inhibitors for Breast Cancer market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the PARP Inhibitors for Breast Cancer companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Everest Pharmaceuticals
Pfizer
Segment by Type
Olaparib
Talazoparib
Segment by Application
Hospital
Clinic
Drug Center
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of PARP Inhibitors for Breast Cancer companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global PARP Inhibitors for Breast Cancer Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Olaparib
1.2.3 Talazoparib
1.3 Market by Application
1.3.1 Global PARP Inhibitors for Breast Cancer Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Drug Center
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global PARP Inhibitors for Breast Cancer Market Perspective (2019-2030)
2.2 PARP Inhibitors for Breast Cancer Growth Trends by Region
2.2.1 Global PARP Inhibitors for Breast Cancer Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 PARP Inhibitors for Breast Cancer Historic Market Size by Region (2019-2024)
2.2.3 PARP Inhibitors for Breast Cancer Forecasted Market Size by Region (2025-2030)
2.3 PARP Inhibitors for Breast Cancer Market Dynamics
2.3.1 PARP Inhibitors for Breast Cancer Industry Trends
2.3.2 PARP Inhibitors for Breast Cancer Market Drivers
2.3.3 PARP Inhibitors for Breast Cancer Market Challenges
2.3.4 PARP Inhibitors for Breast Cancer Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top PARP Inhibitors for Breast Cancer Players by Revenue
3.1.1 Global Top PARP Inhibitors for Breast Cancer Players by Revenue (2019-2024)
3.1.2 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Players (2019-2024)
3.2 Global PARP Inhibitors for Breast Cancer Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by PARP Inhibitors for Breast Cancer Revenue
3.4 Global PARP Inhibitors for Breast Cancer Market Concentration Ratio
3.4.1 Global PARP Inhibitors for Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by PARP Inhibitors for Breast Cancer Revenue in 2023
3.5 PARP Inhibitors for Breast Cancer Key Players Head office and Area Served
3.6 Key Players PARP Inhibitors for Breast Cancer Product Solution and Service
3.7 Date of Enter into PARP Inhibitors for Breast Cancer Market
3.8 Mergers & Acquisitions, Expansion Plans
4 PARP Inhibitors for Breast Cancer Breakdown Data by Type
4.1 Global PARP Inhibitors for Breast Cancer Historic Market Size by Type (2019-2024)
4.2 Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Type (2025-2030)
5 PARP Inhibitors for Breast Cancer Breakdown Data by Application
5.1 Global PARP Inhibitors for Breast Cancer Historic Market Size by Application (2019-2024)
5.2 Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America PARP Inhibitors for Breast Cancer Market Size (2019-2030)
6.2 North America PARP Inhibitors for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America PARP Inhibitors for Breast Cancer Market Size by Country (2019-2024)
6.4 North America PARP Inhibitors for Breast Cancer Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe PARP Inhibitors for Breast Cancer Market Size (2019-2030)
7.2 Europe PARP Inhibitors for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe PARP Inhibitors for Breast Cancer Market Size by Country (2019-2024)
7.4 Europe PARP Inhibitors for Breast Cancer Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size (2019-2030)
8.2 Asia-Pacific PARP Inhibitors for Breast Cancer Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region (2019-2024)
8.4 Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America PARP Inhibitors for Breast Cancer Market Size (2019-2030)
9.2 Latin America PARP Inhibitors for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America PARP Inhibitors for Breast Cancer Market Size by Country (2019-2024)
9.4 Latin America PARP Inhibitors for Breast Cancer Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size (2019-2030)
10.2 Middle East & Africa PARP Inhibitors for Breast Cancer Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country (2019-2024)
10.4 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca PARP Inhibitors for Breast Cancer Introduction
11.1.4 AstraZeneca Revenue in PARP Inhibitors for Breast Cancer Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Everest Pharmaceuticals
11.2.1 Everest Pharmaceuticals Company Detail
11.2.2 Everest Pharmaceuticals Business Overview
11.2.3 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Introduction
11.2.4 Everest Pharmaceuticals Revenue in PARP Inhibitors for Breast Cancer Business (2019-2024)
11.2.5 Everest Pharmaceuticals Recent Development
11.3 Pfizer
11.3.1 Pfizer Company Detail
11.3.2 Pfizer Business Overview
11.3.3 Pfizer PARP Inhibitors for Breast Cancer Introduction
11.3.4 Pfizer Revenue in PARP Inhibitors for Breast Cancer Business (2019-2024)
11.3.5 Pfizer Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
List of Tables
Table 1. Global PARP Inhibitors for Breast Cancer Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Olaparib
Table 3. Key Players of Talazoparib
Table 4. Global PARP Inhibitors for Breast Cancer Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global PARP Inhibitors for Breast Cancer Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global PARP Inhibitors for Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global PARP Inhibitors for Breast Cancer Market Share by Region (2019-2024)
Table 8. Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global PARP Inhibitors for Breast Cancer Market Share by Region (2025-2030)
Table 10. PARP Inhibitors for Breast Cancer Market Trends
Table 11. PARP Inhibitors for Breast Cancer Market Drivers
Table 12. PARP Inhibitors for Breast Cancer Market Challenges
Table 13. PARP Inhibitors for Breast Cancer Market Restraints
Table 14. Global PARP Inhibitors for Breast Cancer Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global PARP Inhibitors for Breast Cancer Market Share by Players (2019-2024)
Table 16. Global Top PARP Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PARP Inhibitors for Breast Cancer as of 2023)
Table 17. Ranking of Global Top PARP Inhibitors for Breast Cancer Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by PARP Inhibitors for Breast Cancer Revenue (CR5 and HHI) & (2019-2024)
Table 19. Key Players Headquarters and Area Served
Table 20. Key Players PARP Inhibitors for Breast Cancer Product Solution and Service
Table 21. Date of Enter into PARP Inhibitors for Breast Cancer Market
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global PARP Inhibitors for Breast Cancer Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Type (2019-2024)
Table 25. Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Type (2025-2030)
Table 27. Global PARP Inhibitors for Breast Cancer Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Application (2019-2024)
Table 29. Global PARP Inhibitors for Breast Cancer Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Application (2025-2030)
Table 31. North America PARP Inhibitors for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America PARP Inhibitors for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America PARP Inhibitors for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe PARP Inhibitors for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe PARP Inhibitors for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe PARP Inhibitors for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America PARP Inhibitors for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America PARP Inhibitors for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America PARP Inhibitors for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Country (2025-2030) & (US$ Million)
Table 46. AstraZeneca Company Detail
Table 47. AstraZeneca Business Overview
Table 48. AstraZeneca PARP Inhibitors for Breast Cancer Product
Table 49. AstraZeneca Revenue in PARP Inhibitors for Breast Cancer Business (2019-2024) & (US$ Million)
Table 50. AstraZeneca Recent Development
Table 51. Everest Pharmaceuticals Company Detail
Table 52. Everest Pharmaceuticals Business Overview
Table 53. Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Product
Table 54. Everest Pharmaceuticals Revenue in PARP Inhibitors for Breast Cancer Business (2019-2024) & (US$ Million)
Table 55. Everest Pharmaceuticals Recent Development
Table 56. Pfizer Company Detail
Table 57. Pfizer Business Overview
Table 58. Pfizer PARP Inhibitors for Breast Cancer Product
Table 59. Pfizer Revenue in PARP Inhibitors for Breast Cancer Business (2019-2024) & (US$ Million)
Table 60. Pfizer Recent Development
Table 61. Research Programs/Design for This Report
Table 62. Key Data Information from Secondary Sources
Table 63. Key Data Information from Primary Sources
List of Figures
Figure 1. Global PARP Inhibitors for Breast Cancer Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global PARP Inhibitors for Breast Cancer Market Share by Type: 2023 VS 2030
Figure 3. Olaparib Features
Figure 4. Talazoparib Features
Figure 5. Global PARP Inhibitors for Breast Cancer Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 6. Global PARP Inhibitors for Breast Cancer Market Share by Application: 2023 VS 2030
Figure 7. Hospital Case Studies
Figure 8. Clinic Case Studies
Figure 9. Drug Center Case Studies
Figure 10. Others Case Studies
Figure 11. PARP Inhibitors for Breast Cancer Report Years Considered
Figure 12. Global PARP Inhibitors for Breast Cancer Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global PARP Inhibitors for Breast Cancer Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global PARP Inhibitors for Breast Cancer Market Share by Region: 2023 VS 2030
Figure 15. Global PARP Inhibitors for Breast Cancer Market Share by Players in 2023
Figure 16. Global Top PARP Inhibitors for Breast Cancer Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in PARP Inhibitors for Breast Cancer as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by PARP Inhibitors for Breast Cancer Revenue in 2023
Figure 18. North America PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America PARP Inhibitors for Breast Cancer Market Share by Country (2019-2030)
Figure 20. United States PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe PARP Inhibitors for Breast Cancer Market Share by Country (2019-2030)
Figure 24. Germany PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific PARP Inhibitors for Breast Cancer Market Share by Region (2019-2030)
Figure 32. China PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America PARP Inhibitors for Breast Cancer Market Share by Country (2019-2030)
Figure 40. Mexico PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa PARP Inhibitors for Breast Cancer Market Share by Country (2019-2030)
Figure 44. Turkey PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia PARP Inhibitors for Breast Cancer Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. AstraZeneca Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2019-2024)
Figure 47. Everest Pharmaceuticals Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2019-2024)
Figure 48. Pfizer Revenue Growth Rate in PARP Inhibitors for Breast Cancer Business (2019-2024)
Figure 49. Bottom-up and Top-down Approaches for This Report
Figure 50. Data Triangulation
Figure 51. Key Executives Interviewed

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock